Jim Gabriele named president and CEO of M2GEN

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Jim Gabriele was named president and chief executive officer of M2GEN.

Gabriele is a data scientist who was most recently senior vice president and chief strategy & data science officer within the Medical Devices Sector at Johnson & Johnson.

M2GEN has linked clinical and genomic databases and runs one of the largest observational research studies in cancer, which tracks patients throughout their lifetime, links longitudinal clinical data with molecular information, and enables a deeper understanding of a patient’s disease.

As senior vice president and chief strategy & data Science officer at Johnson & Johnson, he led global strategy development, pricing strategy, data science, data strategy, digital customer experience and business insights. 

Prior to that, he held senior strategy and data science roles in the Johnson & Johnson Pharmaceutical organization. 

Gabriele succeeds Helge Bastian.

Table of Contents

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login